Cheryl V. Reicin
Cheryl V. Reicin
Partner at Torys LLP
(416) 865-7373
(416) 865-7380
79 Wellington St W, Suite 3000, Box 270, TD Ctr, Toronto, ON
Year called to bar: 1985 (New York); 1989 (Massachusetts)
Cheryl leads the country’s premier life sciences practice. She advises the industry’s largest investors and most innovative start-ups on highly complex transactions worldwide. With an international reputation for quality and helping clients advance their strategies, Cheryl combines deep knowledge of the market with a business-minded practical approach. Cheryl is the leader of Torys’ Life Science practice, a cross-border group in both Canada and the United States. She represents the entire spectrum of biotech, medical device and health technology companies, from start-ups to large public companies, as well as venture capitalists, investment banks and academic medical centers. Cheryl is widely recognized for her long track record of helping life sciences companies at all stages formulate and evolve their domestic and international growth strategies, source capital, and develop and optimize their corporate and tax structures. When clients need transactional counsel in the life sciences sector, Cheryl has extensive experience advising on venture and later-stage financings, IPOs, mergers & acquisitions, licensing transactions and joint ventures or alliances with strategic partners. Prior to joining Torys, Cheryl led the 85-attorney life sciences group of a US law firm.
Cheryl V. Reicin is a featured Leading Lawyer in:
Canadian Legal Lexpert Directory
Consistently Recommended
Cheryl V. Reicin is also listed in the following publication(s)
Read more about Cheryl V. Reicin in ...
Entos' US$400-million research and collaboration agreement with Lilly
Deal aims to develop nucleic acid products targeting central and peripheral nervous system
Roll up in health care sector grows as private equity, strategic players see opportunity
Consolidation is creating larger corporate health care entities
Health sciences are in the pink: renewed interest in life sciences goes beyond COVID
Investors, government and companies are realizing the value and viability of the sector
Canada’s leading biotechnology lawyers
Lexpert presents the Canada’s leading biotechnology lawyers based on the results of our comprehensive yearly peer survey
On July 17, 2017, Norgine B.V., a European specialist pharmaceutical company, acquired all issued and outstanding shares of Merus Labs International Inc. (Merus), pursuant to a plan of arrangement for $1.65 per common share in cash, including the assumption of all debt obligations, for a total enterprise value of approximately $342 million.
On April 21, 2015, Concordia Healthcare Corp. (Concordia), a diverse healthcare company focused on legacy pharmaceutical products and orphan drugs, acquired 18 products from Covis Pharma S.à.r.l and Covis Injectables, S.à.r.l (collectively, Covis). The purchase price of US$1.2 billion was paid in cash at closing.
Cheryl V. Reicin in Mondaq ...